These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 15123527

  • 1. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals.
    Randeva HS, Lewandowski KC, Komorowski J, Murray RD, O'Callaghan CJ, Hillhouse EW, Stepien H, Shalet SM.
    Circulation; 2004 May 25; 109(20):2405-10. PubMed ID: 15123527
    [Abstract] [Full Text] [Related]

  • 2. Plasma total homocysteine concentrations in adults with growth hormone (GH) deficiency: effects of GH replacement.
    Lewandowski KC, Murray RD, Drzewoski J, O'Callaghan CJ, Czupryniak L, Hillhouse EW, Shalet SM, Randeva HS.
    Mol Genet Metab; 2003 Nov 25; 80(3):330-7. PubMed ID: 14680980
    [Abstract] [Full Text] [Related]

  • 3. IGF-1, IGFBP-3, VEGF and MMP-9 levels and their potential relationship with renal functions in patients with compensatory renal growth.
    Yildiz B, Kural N, Colak O, Ak I, Akcar N.
    Clin Physiol Funct Imaging; 2008 Mar 25; 28(2):107-12. PubMed ID: 18093232
    [Abstract] [Full Text] [Related]

  • 4. Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease.
    Lee SD, Chen LM, Kuo WW, Shu WT, Kuo WH, Huang EJ, Tsai CC, Li PC, Liu JY, Chen TH, Huang CY.
    Clin Chim Acta; 2006 May 25; 367(1-2):62-8. PubMed ID: 16406300
    [Abstract] [Full Text] [Related]

  • 5. Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults.
    Murray RD, Randeva HS, Lewandowski KC, Komorowski J, Lawrance JA, Adams JE, Shalet SM.
    Growth Horm IGF Res; 2011 Apr 25; 21(2):96-101. PubMed ID: 21450501
    [Abstract] [Full Text] [Related]

  • 6. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
    Tamura M, Oda M, Matsumoto I, Tsunezuka Y, Kawakami K, Ohta Y, Watanabe G.
    Ann Surg Oncol; 2004 Oct 25; 11(10):928-33. PubMed ID: 15383417
    [Abstract] [Full Text] [Related]

  • 7. New insights into molecular mechanisms of diffuse coronary ectasiae: a possible role for VEGF.
    Savino M, Parisi Q, Biondi-Zoccai GG, Pristipino C, Cianflone D, Crea F.
    Int J Cardiol; 2006 Jan 26; 106(3):307-12. PubMed ID: 16337037
    [Abstract] [Full Text] [Related]

  • 8. Plasma matrix metalloproteinase-9 levels and blood pressure in short children born small for gestational age and effects of growth hormone treatment.
    Willemsen RH, van Dijk M, de Kort SW, van Toorenenbergen AW, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2008 Aug 26; 69(2):264-8. PubMed ID: 18284641
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs.
    Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M, Bergamini PF.
    Leuk Res; 2005 Nov 26; 29(11):1263-9. PubMed ID: 15893373
    [Abstract] [Full Text] [Related]

  • 10. Serum homocysteine concentrations in children with growth hormone (GH) deficiency before and after 12 months GH replacement.
    Esposito V, Di Biase S, Lettiero T, Labella D, Simeone R, Salerno M.
    Clin Endocrinol (Oxf); 2004 Nov 26; 61(5):607-11. PubMed ID: 15521964
    [Abstract] [Full Text] [Related]

  • 11. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
    Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, Fryklund L, Murgatroyd PR, Dunger DB.
    Clin Endocrinol (Oxf); 2005 Oct 26; 63(4):428-36. PubMed ID: 16181235
    [Abstract] [Full Text] [Related]

  • 12. Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow.
    Abd El Aal DE, Mohamed SA, Amine AF, Meki AR.
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb 01; 118(2):219-24. PubMed ID: 15653207
    [Abstract] [Full Text] [Related]

  • 13. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B, Zebrowska A, Wagrowska-Danielewicz M, Kobos J, Waszczykowska E.
    Przegl Lek; 2009 Feb 01; 66(12):1040-5. PubMed ID: 20514902
    [Abstract] [Full Text] [Related]

  • 14. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, Margioris AN.
    Clin Chim Acta; 2007 Apr 01; 379(1-2):31-5. PubMed ID: 17234170
    [Abstract] [Full Text] [Related]

  • 15. Growth factors decrease in subjects with mild to moderate Alzheimer's disease (AD): potential correction with dehydroepiandrosterone-sulphate (DHEAS).
    Luppi C, Fioravanti M, Bertolini B, Inguscio M, Grugnetti A, Guerriero F, Rovelli C, Cantoni F, Guagnano P, Marazzi E, Rolfo E, Ghianda D, Levante D, Guerrini C, Bonacasa R, Solerte SB.
    Arch Gerontol Geriatr; 2009 Apr 01; 49 Suppl 1():173-84. PubMed ID: 19836631
    [Abstract] [Full Text] [Related]

  • 16. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
    Szczepańska-Kostro J, Kowalewski M, Urban M, Gardziejczyk M.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Apr 01; 12(4):257-60. PubMed ID: 17239302
    [Abstract] [Full Text] [Related]

  • 17. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
    Paisley AN, O'Callaghan CJ, Lewandowski KC, Parkinson C, Roberts ME, Drake WM, Monson JP, Trainer PJ, Randeva HS.
    J Clin Endocrinol Metab; 2006 Nov 01; 91(11):4635-40. PubMed ID: 16926249
    [Abstract] [Full Text] [Related]

  • 18. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset.
    Columb B, Smethurst LE, Mukherjee A, Jostel A, Shalet SM, Murray RD.
    Clin Endocrinol (Oxf); 2009 Feb 01; 70(2):281-6. PubMed ID: 18702681
    [Abstract] [Full Text] [Related]

  • 19. [Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy].
    Peczyńska J, Urban M, Urban B, Głowińska B, Florys B.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004 Feb 01; 10(1):41-8. PubMed ID: 15355738
    [Abstract] [Full Text] [Related]

  • 20. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW.
    Eur J Clin Invest; 2005 Sep 01; 35(9):537-45. PubMed ID: 16128859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.